Andrew Feigin

11.0k total citations · 1 hit paper
94 papers, 5.7k citations indexed

About

Andrew Feigin is a scholar working on Neurology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Andrew Feigin has authored 94 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Neurology, 47 papers in Cellular and Molecular Neuroscience and 22 papers in Molecular Biology. Recurrent topics in Andrew Feigin's work include Neurological disorders and treatments (54 papers), Parkinson's Disease Mechanisms and Treatments (38 papers) and Genetic Neurodegenerative Diseases (37 papers). Andrew Feigin is often cited by papers focused on Neurological disorders and treatments (54 papers), Parkinson's Disease Mechanisms and Treatments (38 papers) and Genetic Neurodegenerative Diseases (37 papers). Andrew Feigin collaborates with scholars based in United States, Canada and Italy. Andrew Feigin's co-authors include David Eidelberg, Vijay Dhawan, Chengke Tang, Yilong Ma, Paul J. Mattis, Michael G. Kaplitt, Matthew J. During, Chris C. Tang, Steven J. Frucht and Thomas Eckert and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Andrew Feigin

91 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

2007 775 citations Andrew Feigin, Chengke Tang et al. profile →

Peers

Countries citing papers authored by Andrew Feigin

Since Specialization

Citations

This map shows the geographic impact of Andrew Feigin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Feigin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Feigin more than expected).

Fields of papers citing papers by Andrew Feigin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Feigin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Feigin. The network helps show where Andrew Feigin may publish in the future.

Co-authorship network of co-authors of Andrew Feigin

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Feigin. A scholar is included among the top collaborators of Andrew Feigin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Feigin. Andrew Feigin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases 2025 ·Expert Opinion on Investigational Drugs ·Andrew Feigin, Elizabeth E. Evans, Terrence L. Fisher, Maurice Zauderer	1
2	Huntington’s Disease: New Frontiers in Therapeutics 2021 ·Current Neurology and Neuroscience Reports ·(unknown), Andrew Feigin	45
3	Blood–brain barrier permeability in Parkinson’s disease patients with and without dyskinesia 2021 ·Journal of Neurology ·Koji Fujita, Shichun Peng, Yilong Ma, Chris C. Tang, (unknown), Andrew Feigin, David Eidelberg, Vijay Dhawan	11
4	Visual-Spatial Dysfunction in Parkinson’s Disease: an Exploratory Multimodal Biomarker Study (4024) 2020 ·Neurology ·Alberto Cucca, Amgad Droby, Mahya Beheshti, (unknown), (unknown), (unknown), (unknown), (unknown), Todd E. Hudson, Alessandro Di Rocco, Maria Felice Ghilardi, Matilde Inglese, John‐Ross Rizzo, Milton Biagioni, Andrew Feigin	1
5	Medical, Surgical, and Genetic Treatment of Huntington Disease 2020 ·Neurologic Clinics ·(unknown), Andrew Feigin	26
6	Urodynamic Mechanisms Underlying Overactive Bladder Symptoms in Patients With Parkinson Disease 2019 ·International Neurourology Journal ·(unknown), B. Peyronnet, Jose‐Alberto Palma, Rachael D. Sussman, (unknown), Andrew Feigin, (unknown), Nirit Rosenblum, Steven J. Frucht, Horacio Kaufmann, Victor W. Νitti, Benjamin M. Brucker	9
7	Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort 2018 ·Parkinsonism & Related Disorders ·B. Peyronnet, (unknown), Jose‐Alberto Palma, (unknown), Andrew Feigin, Rachael D. Sussman, Milton Biagioni, (unknown), Rebecca Gilbert, Nirit Rosenblum, Steven J. Frucht, Horacio Kaufmann, Victor W. Νitti, Benjamin M. Brucker	35
8	Outcomes of intradetrusor botulinum toxin injection in patients with Parkinson's disease 2018 ·(unknown), B. Peyronnet, Andrew Feigin, Milton Biagioni, Rebecca Gilbert, Nirit Rosenblum, Steven J. Frucht, Alessandro Di Rocco, Victor W. Νitti, Benjamin M. Brucker	1
9	Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia 2017 ·JCI Insight ·(unknown), Katharina A. Schindlbeck, Chris C. Tang, Martin Niethammer, Yoon Young Choi, (unknown), Amir Nazem, Dominic J. Nardi, (unknown), Andrew Feigin, Yilong Ma, Shichun Peng, Vijay Dhawan, David Eidelberg	16
10	Longitudinal Changes in the Motor Learning-Related Brain Activation Response in Presymptomatic Huntington's Disease 2016 ·PLoS ONE ·Florian Holtbernd, Chris C. Tang, Andrew Feigin, Vijay Dhawan, Maria Felice Ghilardi, Jane S. Paulsen, Mark Guttman, David Eidelberg	7
11	Abnormal metabolic network activity in REM sleep behavior disorder 2014 ·Neurology ·Florian Holtbernd, Jean‐François Gagnon, Ron B. Postuma, Yilong Ma, Chris C. Tang, Andrew Feigin, Vijay Dhawan, Mélanie Vendette, Jean‐Paul Soucy, David Eidelberg, Jacques Montplaisir	137
12	Metabolic network as a progression biomarker of premanifest Huntington’s disease 2013 ·Journal of Clinical Investigation ·Chris C. Tang, Andrew Feigin, Yilong Ma, Christian Habeck, Jane S. Paulsen, Klaus L. Leenders, Laura K. Teune, Joost C.H. van Oostrom, Mark Guttman, Vijay Dhawan, David Eidelberg	86
13	Functional Neuroimaging in Parkinson's Disease 2012 ·Cold Spring Harbor Perspectives in Medicine ·Martin Niethammer, Andrew Feigin, David Eidelberg	53
14	Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease 2008 ·Journal of Neuroscience ·Shigeki Hirano, Kotaro Asanuma, Yilong Ma, Chengke Tang, Andrew Feigin, Vijay Dhawan, Maren Carbon, David Eidelberg	117
15	Implicit and explicit aspects of sequence learning in pre-symptomatic Huntington's disease 2008 ·Parkinsonism & Related Disorders ·M. F. Ghilardi, Gabriella Silvestri, Andrew Feigin, Paul J. Mattis, Dennis J. Zgaljardic, Clara Moisello, Domenica Crupi, Lucio Marinelli, Alessandro Di Rocco, David Eidelberg	40
16	Abnormal metabolic networks in atypical parkinsonism 2008 ·Movement Disorders ·Thomas Eckert, Chengke Tang, Yilong Ma, Nathaniel Brown, Tanya Lin, Steven J. Frucht, Andrew Feigin, David Eidelberg	131
17	Dopaminergic Suppression of Brain Deactivation Responses during Sequence Learning 2008 ·Journal of Neuroscience ·Miklós Árgyelán, Maren Carbon, M. F. Ghilardi, Andrew Feigin, Paul J. Mattis, Chengke Tang, Vijay Dhawan, David Eidelberg	63
18	Relationship Between Self-reported Apathy and Executive Dysfunction in Nondemented Patients With Parkinson Disease 2007 ·Cognitive and Behavioral Neurology ·Dennis J. Zgaljardic, Joan C. Borod, Nancy S. Foldi, (unknown), Paul J. Mattis, Mark Forrest Gordon, Andrew Feigin, David Eidelberg	75
19	A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome 2004 ·American Journal of Kidney Diseases ·James A. Sloand, Mark Shelly, Andrew Feigin, Paul Bernstein, Rebeca D. Monk	154
20	Effect of treatment withL-dopa/carbidopa orL-selegiline on striatal dopamine transporter SPECT imaging with [123I]?-CIT 1999 ·Movement Disorders ·Robert B. Innis, Kenneth Marek, (unknown), Sami S. Zoghbi, (unknown), Andrew Feigin, John Seibyl	109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact